Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary

Abstract

ObjectiveEarly stage primary carcinoma of the fallopian tube (PCFT) is an uncommon condition when strict criteria are applied. The aim of this study was to compare the outcome stage IA-IB PCFT to a matched group of ovarian cancer (OC).MethodsBetween 1990 and 2008, 32 patients with stage IA-IB of PCFT were recorded in the database of three French Institutions. A control group of patients with OC was constituted.ResultsEleven eligible PCFT cases and 29 OC controls fulfilled the stringent inclusion criteria. Median follow-up was 70.2 months. Five-year overall survival was 83.3% (95% confidence interval [CI], 27.3 to 97.5) for PCFT and 88.0% (95% CI, 66.9 to 96.0) for OC (p=0.93). In the subgroup of patients with grade 2-3, the outcome was similar in PCFT compared to OC patients (p=0.75). Five-year relapse-free survival was respectively 62.5% (95% CI, 22.9 to 86.1) and 85.0% (95% CI, 64.6 to 94.2) in the PCFT and OC groups (p=0.07). In the subgroup of patients (grade 2-3), there was no difference between PCFT and OC (p=0.65).ConclusionThe findings did not reveal any difference in prognosis between early stage of PCFT and OC when grade is taken into account. Management of PCFT should mirror that of ovarian carcinoma.

The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer

“…With respect to adjuvant chemotherapy, management of primary fallopian tube cancer is generally similar to ovarian cancer and comparable 5 year survival rates have been reported for stage1a and Stage1b ovarian and fallopian tube cancers. [19,20] Decision making should be individualised through a multidisciplinary forum. It is our practice and that of others to advise adjuvant chemotherapy (carboplatin and paclitaxel) for stage 1c (any grade) or high-grade (grade-3) stage1a and stage1b disease.…”

“…It is our practice and that of others to advise adjuvant chemotherapy (carboplatin and paclitaxel) for stage 1c (any grade) or high-grade (grade-3) stage1a and stage1b disease. [19] The presence of positive cytology would thus affect management of Grade1/2 stage 1a/stage 1b fallopian tube or ovarian cancers. However, some authorities advocate that, chemotherapy should be considered for all stage1 fallopian tube cancers.…”

Primary malignant mixed mullerian tumor of the peritoneum: a case report

“…Systemic adjuvant chemotherapy is essential for all patients after operation. Ifosfamide and cisplatin are usually the preferred chemotherapy regimen, and the reaction rate of ifosfamide is 25% and that of cisplatin as a single drug for uterine carcinosarcoma is 17% ( 13 ). The effect of radiotherapy is controversial for MMMT.…”

A case of recurrent fallopian tube carcinoma in situ with para-aortic lymph node metastasis

“…Management of primary fallopian tube cancer is generally similar to that of ovarian cancer, and comparable 5-year survival rates have been reported for stage 1a and stage 1b ovarian and fallopian tube cancers. Some advise adjuvant chemotherapy (carboplatin and paclitaxel) for stage 1c (any grade) or high-grade (grade 3) stage 1a and stage 1b disease [16]. The presence of positive cytology would thus affect the management of grade 1/2 stage 1a/stage 1b fallopian tube or ovarian cancers.…”